Silver Book Fact

If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.

Johnson S, Diener M, Kaltenboeck A, Binbaum H, et al. An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States. Mov Disord. 2013; 28(3). http://www.ncbi.nlm.nih.gov/pubmed/23404374

Reference

Title
An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States
Publication
Mov Disord
Publication Date
2013
Authors
Johnson S, Diener M, Kaltenboeck A, Binbaum H, et al.
Volume & Issue
Volume 28, Issue 3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient…  
  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…